BNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BNP Paribas Financial Markets lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 60.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 196,225 shares of the biotechnology company’s stock after selling 300,559 shares during the period. BNP Paribas Financial Markets owned 0.09% of BioCryst Pharmaceuticals worth $1,476,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Venturi Wealth Management LLC purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth $46,000. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth $48,000. KBC Group NV increased its stake in BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after buying an additional 4,537 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth $80,000. Finally, Syon Capital LLC purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth $99,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

BCRX has been the subject of a number of analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.56.

BioCryst Pharmaceuticals Trading Up 0.3%

BCRX opened at $10.24 on Monday. The firm has a market cap of $2.14 billion, a P/E ratio of -16.79 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a 12 month low of $5.92 and a 12 month high of $11.11. The stock has a 50-day moving average of $8.11 and a 200 day moving average of $7.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The company’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 EPS. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.